Manganese intoxication and chronic liver failure. Ann Neurol 1994;36:871-875.
Hauser, RA, TA Zesiewicz, AS Rosemurgy, C Martinez, and CW Olanow. 1994. “Manganese Intoxication and Chronic Liver Failure. Ann Neurol 1994;36:871-875.”. Ann Neurol.
Search
Search results
356 results found
Critical drug appraisal. Pergolide. Drug Therapy 1990;20;62-71.
Hauser, RA, and CW Olanow. 1990. “Critical Drug Appraisal. Pergolide. Drug Therapy 1990;20;62-71.”. Drug Therapy.
Parkinson Study Group (including Hauser RA). Safety and efficacy of pramipexole in early Parkinson’s disease. A randomized dose-ranging study. JAMA 1997;278:125-130.
Toward the use of surgical placebo-controlled trials. Transplantation Proceedings1997;29:1925.
Freeman, TB, D Vawter, CG Goetz, PE Leaverton, RA Hauser, PR Sanberg, JH Godbold, and CW Olanow. 1997. “Toward the Use of Surgical Placebo-Controlled Trials. Transplantation Proceedings1997;29:1925.”. Transplantation Proceedings.
Blood manganese correlates with brain magnetic resonance imaging changes in patients with liver disease. Canadian Journal of Neurological Sciences 1996;23:95-98.
Hauser, RA, TA Zesiewicz, C Martinez, AS Rosemurgy, and CW Olanow. 1996. “Blood Manganese Correlates With Brain Magnetic Resonance Imaging Changes in Patients With Liver Disease. Canadian Journal of Neurological Sciences 1996;23:95-98.”. Canadian Journal of Neurological Sciences.
Ropinirole in the treatment of Parkinson’s disease. Expert Opinion on Investigational Drugs 1999;8:697-710.
Zesiewicz, TA, and RA Hauser. 1999. “Ropinirole in the Treatment of Parkinson’s Disease. Expert Opinion on Investigational Drugs 1999;8:697-710.”. Expert Opinion on Investigational Drugs.
Depression and Anxiety in Parkinson’s Disease. American Journal of Geriatric Psychiatry. 1999;7:110-118.
Zesiewicz, TA, M Gold, G Chari, and RA Hauser. 1999. “Depression and Anxiety in Parkinson’s Disease. American Journal of Geriatric Psychiatry. 1999;7:110-118.”. Am J Geriatr Psych.
Clinical trials of add-on medications in Parkinson’s disease: efficacy versus usefulness. Parkinsonism & Related Disorders 1997;3:1-6.
Hauser, RA, TA Zesiewicz, SA Factor, M Guttman, and WJ Weiner. 1997. “Clinical Trials of Add-on Medications in Parkinson’s Disease: Efficacy versus Usefulness. Parkinsonism & Related Disorders 1997;3:1-6.”. Parkinsonism and Related Disorders.
A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology 2001;56:455-462.
Group, Parkinson Study. 2001. “A Randomized, Controlled Trial of Remacemide For Motor Fluctuations in Parkinson’s Disease. Neurology 2001;56:455-462.”. Neurology.
Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.
Hauser, RA, H Barkay, HH Fernandez, J Jimenez-Shahed, SA Factor, N Gross, L Marinelli, et al. 2024. “Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.”. J Clin Psychopharmacol. 2024 Jul-Aug 01;44(4):386-396. Doi: 10.1097/JCP.0000000000001885. Epub 2024 Jun 21.PMID: 38901008.